Penetrium Bioscience Unveils Breakthrough Mechanism
Opening a New Era for Targeted Cancer Therapy
Penetrium Bioscience (KOSDAQ 187660) has disclosed compelling new scientific evidence [April 17, 2026] that, for the first time elucidates the fundamental mechanism behind the long-standing “Seed & Soil” theory, which was initially proposed by Stephen Paget in 1889.
The results demonstrate that the efficacy of targeted therapies is profoundly restricted by pathological tumour microenvironments (“soil”), and Penetrium’s innovative approach effectively circumvents this obstacle.The data introduces a paradigm-shifting mechanism that directly addresses the long-standing challenge of sub-lethal drug exposure, a significant factor in therapeutic resistance in oncology.
Penetrium Bioscience is a South Korean drug development company that concentrates on the development of next-generation therapeutics that target the fundamental biological ecosystems that underlie disease. The company is developing platform technologies that are specifically designed to address cancer, autoimmune diseases, and other intractable conditions by utilising advanced drug delivery systems and AI-driven discovery.
A fundamental transition: from the targeting of cancer cells to the normalisation of the tumour ecosystem
For decades, the primary focus of oncology drug development has been the targeting of cancer cells (“seed”) through genetic and molecular pathways. Penetrium Bioscience’s recent discoveries indicate that the tumour microenvironment (“soil”) is the true source of resistance, as it impedes the ability of medications to achieve effective cytotoxic concentrations.Professor Jinho Choy, keynote speaker at a scientific symposium at the National Press Club in Seoul, suggested that the fundamental error in contemporary oncology has been the presumption that resistance is rooted in the cancer cell. “In reality, the tumour microenvironment establishes a protective barrier that diminishes drug exposure to sub-lethal levels, thereby inducing adaptive resistance.”
This barrier is directly targeted by Penetrium’s mechanism. The therapeutic disrupts the tumour’s protective ecosystem by modulating pathological macrophages and cancer-associated fibroblasts (CAFs), thereby allowing co-administered therapies to reach full lethal concentrations at the tumour site.
This method not only improves therapeutic efficacy but also prevents the emergence of adaptive resistance at its source.
Independent Validation Verifies Mechanistic Consistency
The findings were independently verified through collaborative investigations conducted by Seoul National University Hospital and KAIST (Korea Advanced Institute of Science and Technology). These studies have verified that the observed effects of Penetrium in pathological models are entirely consistent with the RNA sequencing (RNA-seq) data obtained from pancreatic cancer organoids.
This alignment offers compelling evidence that Penetrium’s mechanism is not restricted to a particular tumour type, but rather serves as a platform that is extensively applicable for the normalisation of the microenvironment across a diversity of cancers.
Addressing the Root Cause of the “Sub-Lethal Dose” Issue
This research has a critical implication in the resolution of the “sub-lethal dose” dilemma, which is characterised by insufficient drug exposure, which results in incomplete tumour elimination and ultimately, resistance.
Penetrium facilitates the attainment of effective lethal concentrations by dismantling the tumor’s physical and biological defence systems. Consequently,
• Eliminating the conditions that promote adaptive resistance
• Enhancing the duration of current targeted therapies
• The potential to restore the efficacy of blockbuster medications that have been restricted by resistance
Strategic Positioning as a Global Combination Therapy Partner
“Penetrium is not intended to compete with existing therapies, but rather to unlock their full potential,” stated Dr. Wondong Cho, Chairman & CEO of Penetrium Bioscience. “We perceive substantial opportunities to collaborate with global pharmaceutical companies in order to enhance and broaden the efficacy of targeted therapies that have been restricted by resistance.”
CEO & Chairman, Penetrium BioScience Dr Wondong Cho
The company is currently engaged in the pursuit of strategic collaborations with global biopharma partners to incorporate Penetrium into combination therapy regimens across oncology indications. The organisation’s objective is to establish Penetrium as a pioneering microenvironment-normalizing platform that has the potential to revolutionise therapeutic strategies in oncology and beyond.
Picture Source: Penetrium Bioscience